Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2328647 | 0.98 | SIGMAR1 (0.65) | SIGMAR1TMEM97ABCB1LTA4H | |
| SCHEMBL1299275 | 0.98 | SIGMAR1 (0.69) | SIGMAR1TMEM97LTA4H | |
| Hydrochloric Acid SCHEMBL1298985 | 0.97 | SIGMAR1 (0.67) | SIGMAR1TMEM97LTA4H | |
| SCHEMBL2331362 | 0.91 | MAPT (0.67) | SIGMAR1TMEM97HRH3 | |
| Hydrochloric Acid SCHEMBL2332802 | 0.89 | MAPT (0.65) | SIGMAR1TMEM97HRH3 | |
| SCHEMBL13004967 | 0.85 | KDM4E (0.62) | SIGMAR1HRH3 | |
| SCHEMBL16225992 | 0.82 | KMT2A (0.59) | SIGMAR1HRH3 | |
| SCHEMBL2166450 | 0.82 | SIGMAR1 (0.67) | SIGMAR1 | |
| SCHEMBL6550825 | 0.82 | SIGMAR1 (1.00) | SIGMAR1LTA4H | |
| SCHEMBL2962629 | 0.82 | SIGMAR1 (1.00) | SIGMAR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102197028-A | Piperidine derivative and piperazine derivative, and therapeutic agent for diseases associated with central nervous system disorders | MS SCIENCE CORP | 2011-09-21 | — | — | CN | claimed |
| EP-2357171-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | M's Science Corporation (JP) | 2011-08-17 | — | — | EP | claimed |
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | THE CLEVELAND CLINIC FOUNDATION | 2023-08-17 | — | — | US | disclosed |
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | THE CLEVELAND CLINIC FOUNDATION | 2023-08-17 | — | — | US | disclosed |
| WO-2022006518-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20110263862-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | M'S SCIENCE CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263862-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | M'S SCIENCE CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263862-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | M'S SCIENCE CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| CN-102197028-A | Piperidine derivative and piperazine derivative, and therapeutic agent for diseases associated with central nervous system disorders | MS SCIENCE CORP | 2011-09-21 | — | — | CN | disclosed |
| EP-2357171-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | M's Science Corporation (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | CHAT, DCX, GAP43 | SIGMAR1 4523/4885TMEM97 3333/4885ABCB1 4318/4885 |
| US-20110263862-A1 | PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS | SIGMAR1, OPRL1, OPRK1 | SIGMAR1 1/4885TMEM97 4/4885ABCB1 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.